Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

TYSABRI 300 mg concentrate for solution for infusion

Active Ingredient:
natalizumab
Company:  
Biogen Idec Ltd See contact details
ATC code: 
L04AG03
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Alert Card

Patient alert card regarding PML risk when using Tysabri

{pdf_link}

Physician Information and Management Guidelines for Patients with Multiple Sclerosis receiving TYSABRI Therapy

{healthcare_pro_orange} For Healthcare Professionals

Physician information regarding PML risk for Tysabri

{pdf_link}

Treatment Continuation Form

{healthcare_pro_orange} For Healthcare Professionals

Treatment continuation form for HCPs for IV and SC presentations

{pdf_link}

Treatment Discontinuation Form

{healthcare_pro_orange} For Healthcare Professionals

Treatment discontinuation form for HCPs for IV and SC presentations

{pdf_link}

Treatment Initiation Form

{healthcare_pro_orange} For Healthcare Professionals

Treatment initiation form for Tysabri

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Biogen Idec Ltd
Company image
Address
5 Foundation Park, Roxborough Way, Maidenhead, Berkshire, SL6 3UD, UK
Medical Information e-mail
[email protected]
Medical Information Direct Line
0800 008 7401
Medical Information Fax
+44 (0)1628 501 010